Teva Pharmaceutical Industries Limited
TEVA
$16.33
-$0.13-0.79%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 50.34% | 48.35% | -508.63% | -130.02% | 571.01% |
| Total Depreciation and Amortization | 3.86% | 0.00% | -4.78% | 2.26% | -6.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 38.63% | -20.86% | 191.67% | 47.24% | 235.83% |
| Change in Net Operating Assets | -177.29% | 3,270.00% | 97.99% | -270.21% | 228.63% |
| Cash from Operations | -17.03% | 572.82% | 183.06% | -110.47% | 23,580.00% |
| Capital Expenditure | 12.84% | -52.58% | 21.77% | -4.20% | 20.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -89.47% | 3,700.00% | -- | -- | -100.00% |
| Other Investing Activities | -13.49% | 37.96% | -3.18% | -32.62% | 30.03% |
| Cash from Investing | -24.63% | 50.56% | 23.61% | -52.16% | 63.59% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 58.33% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 93.38% | -98.68% | 0.00% |
| Cash from Financing | -- | -- | -539.74% | 73.78% | 0.00% |
| Foreign Exchange rate Adjustments | -221.00% | 304.08% | 52.88% | -252.94% | 306.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 200.00% | -- | -- |
| Net Change in Cash | -101.79% | 244.75% | -210.59% | -124.16% | 332.62% |
